Download PDF
Pharmacopsychiatry
DOI: 10.1055/a-2286-1427
Original Paper

Comparable Psychotropic Prescription Rates After Hospital Discharge Between Patients with COVID-19 and Those With Non-COVID-19-Related Respiratory Infection

Yuna Takahashi   ‡
1   Division of Drug Informatics, Keio University Faculty of Pharmacy, Tokyo, Japan
,
Taisuke Yatomi   ‡
2   Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
,
Naohito Yamaguchi
3   Saiseikai Research Institute of Health Care and Welfare, Tokyo, Japan
,
Kimio Yoshimura
4   Department of Health Policy and Management, Keio University School of Medicine, Tokyo, Japan
,
Satoko Hori
1   Division of Drug Informatics, Keio University Faculty of Pharmacy, Tokyo, Japan
,
Hiroyuki Uchida
2   Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Introduction Whether psychiatric symptoms after recovery from coronavirus disease 2019 (COVID-19) are specific to this illness remains unclear.

Methods In this retrospective study, the Diagnosis Procedure Combination data and outpatient clinic data were used for patients who received inpatient treatment in Saiseikai-affiliated hospitals for COVID-19 or other respiratory tract infections (non-COVID) from 2020 to 2022. The primary outcome was new prescriptions of psychotropic drugs after discharge (i. e., prescriptions of psychotropics to patients who had not received them before or during their hospitalization). Values of interest were compared between groups using the chi-square test or Fisher’s exact test. A COX proportional-hazards model was used to examine factors associated with psychotropic prescriptions after discharge in age- and sex-matched COVID-19 and non-COVID patients.

Results Of 31,993 chart records, 19,613 were excluded due to a positive history with psychiatric disorders (n=2,445), prescriptions of psychotropics (n=744), and no follow-ups (n=16,424). Thus, 3,648 COVID-19 and 8,732 non-COVID patients were included (mean [range] duration of follow-up, days: 146.9 [1–727] and 239.2 [1–729], respectively). Two hundred and four (5.6%) of the 3,648 patients with COVID-19 received psychotropic prescriptions after discharge. No statistically significant differences were observed in the prescription rates of any psychotropic category between the COVID-19 and non-COVID groups. An increase in severity during hospitalization was significantly associated with more frequent psychotropic prescriptions (hazard ratio 1.83, p<0.001).

Discussion The development of psychiatric symptoms should be closely observed, especially in patients who experienced increased severity during hospitalization, regardless of whether they suffered from COVID-19.

Keywords

coronavirus disease 2019 - COVID-19 - hypnotics - psychotropics

‡ These authors contributed to this work equally: Yuna Takahashi1, Taisuke Yatomi.


Supplementary Material



Publication History

Received: 20 November 2023

Accepted after revision: 04 March 2024

Article published online:
26 March 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Moreno C, Wykes T, Galderisi S. et al. How mental health care should change as a consequence of the COVID-19 pandemic. Lancet Psychiatry 2020; 7: 813-824
    CrossrefPubMedGoogle Scholar
  • 2 Soriano JB, Murthy S, Marshall JC. et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022; 22: e102-e107
    CrossrefPubMedGoogle Scholar
  • 3 Frontera JA, Yang D, Medicherla C. et al. Trajectories of neurologic recovery 12 months after hospitalization for COVID-19: A prospective longitudinal study. Neurology 2022; 99: e33-e45
    CrossrefPubMedGoogle Scholar
  • 4 Kayaaslan B, Eser F, Kalem AK. et al. Post-COVID syndrome: A single-center questionnaire study on 1007 participants recovered from COVID-19. J Med Virol 2021; 93: 6566-6574
    CrossrefPubMedGoogle Scholar
  • 5 Bai F, Tomasoni D, Falcinella C. et al. Female gender is associated with long COVID syndrome: A prospective cohort study. Clin Microbiol Infect 2022; 28: 611.e619-611.e616
    PubMedGoogle Scholar
  • 6 Buonsenso D, Gennaro LD, Rose CD. et al. Long-term outcomes of pediatric infections: From traditional infectious diseases to long Covid. Future Microbiol 2022; 17: 551-571
    CrossrefPubMedGoogle Scholar
  • 7 Abel KM, Carr MJ, Ashcroft DM. et al Association of SARS-CoV-2 infection with psychological distress, psychotropic prescribing, fatigue, and sleep problems among UK primary care patients. JAMA Netw Open 2021; 4: e2134803 3
    CrossrefPubMedGoogle Scholar
  • 8 Xiong Q, Xu M, Li J. et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: A single-centre longitudinal study. Clin Microbiol Infect 2021; 27: 89-95
    CrossrefPubMedGoogle Scholar
  • 9 Ganesh A, Rosentreter RE, Chen Y. et al. Patient-reported outcomes of neurologic and neuropsychiatric symptoms in mild COVID-19: A prospective cohort study. CMAJ Open 2023; 11: E696-E705
    CrossrefPubMedGoogle Scholar
  • 10 Lovik A, González-Hijón J, Hoffart A. et al. Elevated symptoms of depression and anxiety among family members and friends of critically ill COVID-19 patients – an observational study of five cohorts across four countries. Lancet Reg Health Eur 2023; 33: 100733
    CrossrefPubMedGoogle Scholar
  • 11 Vivaldi G, Pfeffer PE, Talaei M. et al. Long-term symptom profiles after COVID-19 vs other acute respiratory infections: An analysis of data from the COVIDENCE UK study. EClinicalMedicine 2023; 102251
    CrossrefPubMedGoogle Scholar
  • 12 R Development Core Team. R: A Language and Environment for Statistical Computing. In. Vienna, Austria: R Foundation for Statistical Computing; 2021
    Google Scholar
  • 13 Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013; 48: 452-458
    CrossrefPubMedGoogle Scholar
  • 14 Azizi A, Achak D, Saad E. et al. Post-COVID-19 mental health and its associated factors at 3-months after discharge: A case-control study. Clin Epidemiol Glob Health 2022; 17: 101141-101141
    CrossrefPubMedGoogle Scholar
  • 15 Taquet M, Luciano S, Geddes JR. et al. Bidirectional associations between COVID-19 and psychiatric disorder: Retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry 2021; 8: 130-140
    CrossrefPubMedGoogle Scholar
  • 16 Ishikawa H, Tachimori H, Takeshima T. et al. Prevalence, treatment, and the correlates of common mental disorders in the mid 2010’s in Japan: The results of the world mental health Japan 2nd survey. J Affect Disord 2018; 241: 554-562
    CrossrefPubMedGoogle Scholar
  • 17 Vardar-Yagli N, Saglam M, Savci S. et al. Impact of sleep quality on functional capacity, peripheral muscle strength and quality of life in patients with chronic obstructive pulmonary disease. . Expert Rev Respir Med 2015; 9: 233-239
    CrossrefPubMedGoogle Scholar
  • 18 Al-Harbi A, Alanazi T, Alghamdi H. et al. Prevalence of insomnia among patients with bronchial asthma. J Asthma Allergy 2022; 15: 111-116
    CrossrefPubMedGoogle Scholar
  • 19 Zeng N, Zhao Y-M, Yan W. et al. A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: Call for research priority and action. Mol Psychiatry 2023; 28: 423-433
    CrossrefPubMedGoogle Scholar
  • 20 Zohar J, Stahl S, Moller H-J. et al. A review of the current nomenclature for psychotropic agents and an introduction to the neuroscience-based nomenclature. Eur Neuropsychopharmacol 2015; 25: 2318-2325
    CrossrefPubMedGoogle Scholar
  • 21 Tenforde MW, Self WH, Adams K. et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA 2021; 326: 2043-2054
    CrossrefPubMedGoogle Scholar
  • 22 Hoertel N, Sánchez-Rico M, Vernet R. et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: Results from an observational study. Mol Psychiatry 2021; 26: 5199-5212
    CrossrefPubMedGoogle Scholar
  • 23 Bonnet U, Juckel G. COVID-19 outcomes: Does the use of psychotropic drugs make a difference? Accumulating evidence of a beneficial effect of antidepressants—a scoping review. J Clin Psychopharmacol 2022; 25: 2318-2325
    PubMedGoogle Scholar
  • 24 Mueller JK, Riederer P, Müller WE. Neuropsychiatric drugs against COVID-19: What is the clinical evidence?. Pharmacopsychiatry 2022; 55: 7-15
    Article in Thieme ConnectPubMedGoogle Scholar